*Disclaimer

ADALTA LIMITED (ASX: 1AD)

🔗 📄 📈

1AD: New AD-214 data de-risks clinical studies

ADALTA LIMITED

2023-07-07 08:22:00

1AD: AD-214 clinical trial approval

ADALTA LIMITED

2023-06-29 08:21:00

1AD: Rights Offer results

ADALTA LIMITED

2023-05-25 08:23:00

1AD: Rights Offer to fund early return to clinic and growth

ADALTA LIMITED

2023-04-28 09:36:00

1AD: Publication highlights I-body potential in osteoporosis

ADALTA LIMITED

2023-01-25 09:14:00

1AD: AdAlta welcomes new substantial shareholders

ADALTA LIMITED

2023-01-24 09:21:00

1AD: Second Japan patent for AD-214

ADALTA LIMITED

  1. AdAlta Limited has been granted a second Japanese patent relating to its lead program, AD-214.
  2. The patent is directed to polypeptides containing the binding loops of the company’s lead i-body AD-214.
  3. The patent coverage extends to i-bodies that are related to AD-214 for treating CXCR4-related diseases or disorders which includes the lead indication of idiopathic pulmonary fibrosis as well as cancer, viral infections, inflammatory diseases, sclerosis, kidney disease, eye disorders and immune deficiency disorder s and wounds

2023-01-10 08:20:00